Wells Fargo & Company MN decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 124,298 shares of the biopharmaceutical company’s stock after selling 11,020 shares during the period. Wells Fargo & Company MN owned about 0.13% of Alnylam Pharmaceuticals worth $15,793,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Bailard Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $445,000. WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at $10,633,000. California Public Employees Retirement System increased its stake in Alnylam Pharmaceuticals by 5.1% during the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock valued at $15,650,000 after purchasing an additional 6,506 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Bank of New York Mellon Corp now owns 342,105 shares of the biopharmaceutical company’s stock valued at $40,194,000 after purchasing an additional 8,163 shares during the last quarter. Finally, Orbimed Advisors LLC increased its stake in Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after purchasing an additional 445,600 shares during the last quarter. Hedge funds and other institutional investors own 92.44% of the company’s stock.
In related news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the transaction, the senior vice president now owns 17,749 shares in the company, valued at approximately $2,151,178.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $129.00, for a total transaction of $1,935,000.00. Following the completion of the transaction, the director now owns 155,795 shares of the company’s stock, valued at approximately $20,097,555. The disclosure for this sale can be found here. Insiders sold a total of 57,994 shares of company stock valued at $7,527,653 in the last quarter. 4.30% of the stock is currently owned by insiders.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The company had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The business’s quarterly revenue was up 116.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.32) EPS. sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.88 EPS for the current fiscal year.
Several research firms have recently commented on ALNY. Credit Suisse Group set a $151.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. B. Riley lowered their price target on shares of Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating for the company in a research report on Friday, February 16th. BMO Capital Markets lowered their price target on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, January 19th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research report on Sunday, January 7th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $126.89.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/wells-fargo-company-mn-sells-11020-shares-of-alnylam-pharmaceuticals-inc-alny.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.